Overview

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Capital Medical University
Collaborators:
Duke University
Geneplus-Beijing Co. Ltd.
Treatments:
Cisplatin